пятница, 26 августа 2016 г.

Lung cancer doctors eye Merck's Keytruda over Bristol's Opdivo

Lung cancer doctors eye Merck's Keytruda over Bristol's Opdivo


Recent clinical trial results are likely to lead doctors to treat more patients who have a common form of lung cancer with a Merck drug at the expense of a Bristol-Myers Squibb medication at least until more data emerges, oncologists and analysts say. The yet-to-be-published studies involve drugs in a new class designed to enable the body's immune system to fight cancer.



from Biotech News